Recruiting PHASE3 INTERVENTIONAL 1-arm
NCT07232134
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia (AML-DS-2025)
Prospective Non-randomized Multicenter Trial: the Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Updated 1 time since 2025 Last updated: Nov 17, 2025 Started: Jul 24, 2025 Primary completion: Jul 24, 2030 Completion: Dec 30, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on AML (Acute Myelogenous Leukemia) and Down Syndrome (DS), this trial is actively recruiting participants. The trial is conducted by Federal Research Institute of Pediatric Hematology, Oncology and Immunology and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Data source: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
For direct contact, visit the study record on ClinicalTrials.gov .